Examination of the effectiveness of early diagnosis and treatment performed by magnetic resonance imaging (MRI) of hepatocellular carcinoma with liver specific contrast agent.
Phase 4
- Conditions
- Targeted to chronic liver disease patients undergoing abdominal ultrasonography in regular intervals, diagnosed the early hepatocellular carcinoma or more than 2cm 1.0cm.
- Registration Number
- JPRN-UMIN000009830
- Lead Sponsor
- Gastroenterology of the university of Tokyo hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
Not provided
Exclusion Criteria
Cases correspond to the following exclusion criteria at the time of registration are excluded from the scope. Cases of liver dysfunction or more points 9 Child-Pugh score Failure in patients with severe hepatic, there are reports that the rate of excretion into feces after administration of gadolinium has dropped to 6%. Patients with renal impairment than eGFR 30mL/min In patients with severe renal impairment, in patients who spoke a foreign nephrogenic systemic fibrosis after gadolinium-based contrast agent other use has been reported Patients with severe heart disease Patients with severe respiratory disease If the physician has deemed inappropriate sharing research or study investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Entry period is three years, and observation period is five years. Comparison the time to recurrence other than the treatment site, or onset naive HCC from the randomization.
- Secondary Outcome Measures
Name Time Method In case of observation for the nodule according to the pathological diagnosis, compare and investigate the rate of progression to hepatocellular carcinoma and overall survival.